SVB Leerink

The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.

The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations. 

BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating. 

Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.

Cowen and Leerink rated Quanterix at Outperform while JP Morgan initiated coverage with an Overweight rating — the banks managed the company's $74 million IPO.

The investment bank gave Exact Sciences' shares a price target of $30, and said it expects higher uptake of the Cologuard test and an increase in payor contracts. 

The investment bank also cited challenges for Illumina in penetrating the clinical diagnostics markets and driving physician adoption of its tests.

The investment bank noted increased traction for Invitae's test, a "massive" market opportunity, and potential clinical and payor adoption of the firm's technology. 

The investment bank said the quick approval by the FDA for T2 Bio's platform and Candida test could signal high interest for the product in the medical community. 

The downgrade follows Roche's proposed bid to acquire a majority stake in the company.